CA1269043A - Compositions therapeutiques flottantes a liberation lente - Google Patents

Compositions therapeutiques flottantes a liberation lente

Info

Publication number: CA1269043A
Authority: CA; Canada
Prior art keywords: parts; water; tablet; gelling; agar
Prior art date: 1985-04-12
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired

Application number

CA000505778A

Other languages

English (en)

Other versions

CA1269043C (fr

Inventor

Sanford Bolton

Subhash Desai

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Forest Laboratories LLC

Original Assignee

Forest Laboratories LLC

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1985-04-12

Filing date

1986-04-03

Publication date

1990-05-15

1986-04-03 Application filed by Forest Laboratories LLC filed Critical Forest Laboratories LLC

1986-04-03 Priority to CA000505778A priority Critical patent/CA1269043A/fr

1987-03-17 Priority claimed from US07/026,640 external-priority patent/US4814179A/en

1990-05-15 Application granted granted Critical

1990-05-15 Publication of CA1269043C publication Critical patent/CA1269043C/fr

1990-05-15 Publication of CA1269043A publication Critical patent/CA1269043A/fr

Status Expired legal-status Critical Current

Links

239000000203 mixture Substances 0.000 title claims abstract description 80
230000001225 therapeutic effect Effects 0.000 title claims abstract description 15
238000013268 sustained release Methods 0.000 title abstract description 10
239000012730 sustained-release form Substances 0.000 title abstract description 10
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 56
239000003349 gelling agent Substances 0.000 claims abstract description 48
239000003814 drug Substances 0.000 claims abstract description 47
229920001817 Agar Polymers 0.000 claims abstract description 40
239000008272 agar Substances 0.000 claims abstract description 40
229940124597 therapeutic agent Drugs 0.000 claims abstract description 33
210000004051 gastric juice Anatomy 0.000 claims abstract description 12
239000003826 tablet Substances 0.000 claims description 81
ZFXYFBGIUFBOJW-UHFFFAOYSA-N theophylline Chemical group O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 claims description 78
235000010419 agar Nutrition 0.000 claims description 39
229960000278 theophylline Drugs 0.000 claims description 39
239000003921 oil Substances 0.000 claims description 30
239000002480 mineral oil Substances 0.000 claims description 19
235000010446 mineral oil Nutrition 0.000 claims description 19
238000001035 drying Methods 0.000 claims description 13
229920000161 Locust bean gum Polymers 0.000 claims description 12
229940059904 light mineral oil Drugs 0.000 claims description 12
239000000711 locust bean gum Substances 0.000 claims description 12
235000010420 locust bean gum Nutrition 0.000 claims description 12
238000000034 method Methods 0.000 claims description 12
239000000679 carrageenan Substances 0.000 claims description 11
235000010418 carrageenan Nutrition 0.000 claims description 11
229920001525 carrageenan Polymers 0.000 claims description 11
229940113118 carrageenan Drugs 0.000 claims description 11
239000007891 compressed tablet Substances 0.000 claims description 11
239000000499 gel Substances 0.000 claims description 11
UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 11
AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 9
239000000783 alginic acid Substances 0.000 claims description 8
235000010443 alginic acid Nutrition 0.000 claims description 8
229920000615 alginic acid Polymers 0.000 claims description 8
229960001126 alginic acid Drugs 0.000 claims description 8
150000004781 alginic acids Chemical class 0.000 claims description 8
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 claims description 8
229960000830 captopril Drugs 0.000 claims description 8
239000012530 fluid Substances 0.000 claims description 7
230000002496 gastric effect Effects 0.000 claims description 7
ZNOZWUKQPJXOIG-XSBHQQIPSA-L [(2r,3s,4r,5r,6s)-6-[[(1r,3s,4r,5r,8s)-3,4-dihydroxy-2,6-dioxabicyclo[3.2.1]octan-8-yl]oxy]-4-[[(1r,3r,4r,5r,8s)-8-[(2s,3r,4r,5r,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-sulfonatooxyoxan-2-yl]oxy-4-hydroxy-2,6-dioxabicyclo[3.2.1]octan-3-yl]oxy]-5-hydroxy-2-( Chemical compound O[C@@H]1[C@@H](O)[C@@H](OS([O-])(=O)=O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H]2OC[C@H]1O[C@H](O[C@H]1[C@H]([C@@H](CO)O[C@@H](O[C@@H]3[C@@H]4OC[C@H]3O[C@H](O)[C@@H]4O)[C@@H]1O)OS([O-])(=O)=O)[C@@H]2O ZNOZWUKQPJXOIG-XSBHQQIPSA-L 0.000 claims description 6
229960000723 ampicillin Drugs 0.000 claims description 6
239000011159 matrix material Substances 0.000 claims description 6
238000001816 cooling Methods 0.000 claims description 5
238000001727 in vivo Methods 0.000 claims description 5
239000002552 dosage form Substances 0.000 claims description 4
238000001879 gelation Methods 0.000 claims description 4
239000001509 sodium citrate Substances 0.000 claims description 4
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 4
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 3
239000004227 calcium gluconate Substances 0.000 claims description 3
229960004494 calcium gluconate Drugs 0.000 claims description 3
235000013927 calcium gluconate Nutrition 0.000 claims description 3
NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 3
239000008101 lactose Substances 0.000 claims description 3
229940042472 mineral oil Drugs 0.000 claims 13
239000007916 tablet composition Substances 0.000 claims 10
229940023476 agar Drugs 0.000 claims 3
239000007858 starting material Substances 0.000 claims 2
239000000416 hydrocolloid Substances 0.000 abstract description 5
239000007939 sustained release tablet Substances 0.000 abstract 1
238000009472 formulation Methods 0.000 description 17
235000019198 oils Nutrition 0.000 description 12
239000004615 ingredient Substances 0.000 description 9
238000007922 dissolution test Methods 0.000 description 8
229940079593 drug Drugs 0.000 description 8
239000000047 product Substances 0.000 description 7
210000002784 stomach Anatomy 0.000 description 6
229930182555 Penicillin Natural products 0.000 description 5
JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
238000007605 air drying Methods 0.000 description 5
239000002775 capsule Substances 0.000 description 5
230000001186 cumulative effect Effects 0.000 description 5
229940049954 penicillin Drugs 0.000 description 5
239000000243 solution Substances 0.000 description 5
230000000694 effects Effects 0.000 description 4
210000000936 intestine Anatomy 0.000 description 4
239000000725 suspension Substances 0.000 description 4
239000011324 bead Substances 0.000 description 3
239000012467 final product Substances 0.000 description 3
238000003756 stirring Methods 0.000 description 3
238000012360 testing method Methods 0.000 description 3
RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 2
229920002125 Sokalan® Polymers 0.000 description 2
239000002253 acid Substances 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
229940069428 antacid Drugs 0.000 description 2
239000003159 antacid agent Substances 0.000 description 2
239000007864 aqueous solution Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
244000309464 bull Species 0.000 description 2
239000001913 cellulose Chemical class 0.000 description 2
229920002678 cellulose Chemical class 0.000 description 2
230000001684 chronic effect Effects 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
239000012738 dissolution medium Substances 0.000 description 2
210000001035 gastrointestinal tract Anatomy 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
238000002360 preparation method Methods 0.000 description 2
LOUPRKONTZGTKE-LHHVKLHASA-N quinidine Chemical compound C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@H]2[C@@H](O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-LHHVKLHASA-N 0.000 description 2
150000003839 salts Chemical class 0.000 description 2
239000002904 solvent Substances 0.000 description 2
VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
229920000936 Agarose Polymers 0.000 description 1
GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
244000247812 Amorphophallus rivieri Species 0.000 description 1
235000001206 Amorphophallus rivieri Nutrition 0.000 description 1
229930003347 Atropine Natural products 0.000 description 1
239000004215 Carbon black (E152) Substances 0.000 description 1
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
AIKKULXCBHRFOS-UHFFFAOYSA-N Formothion Chemical compound COP(=S)(OC)SCC(=O)N(C)C=O AIKKULXCBHRFOS-UHFFFAOYSA-N 0.000 description 1
RKUNBYITZUJHSG-UHFFFAOYSA-N Hyosciamin-hydrochlorid Natural products CN1C(C2)CCC1CC2OC(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-UHFFFAOYSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229920002752 Konjac Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
208000007107 Stomach Ulcer Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
239000000654 additive Substances 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
230000000578 anorexic effect Effects 0.000 description 1
239000000730 antalgic agent Substances 0.000 description 1
239000003242 anti bacterial agent Substances 0.000 description 1
230000003178 anti-diabetic effect Effects 0.000 description 1
230000002921 anti-spasmodic effect Effects 0.000 description 1
229940088710 antibiotic agent Drugs 0.000 description 1
229940125715 antihistaminic agent Drugs 0.000 description 1
239000000739 antihistaminic agent Substances 0.000 description 1
239000002579 antinauseant Substances 0.000 description 1
229940124575 antispasmodic agent Drugs 0.000 description 1
238000013459 approach Methods 0.000 description 1
239000007900 aqueous suspension Substances 0.000 description 1
RKUNBYITZUJHSG-SPUOUPEWSA-N atropine Chemical compound O([C@H]1C[C@H]2CC[C@@H](C1)N2C)C(=O)C(CO)C1=CC=CC=C1 RKUNBYITZUJHSG-SPUOUPEWSA-N 0.000 description 1
229960000396 atropine Drugs 0.000 description 1
230000004888 barrier function Effects 0.000 description 1
230000009286 beneficial effect Effects 0.000 description 1
239000008280 blood Substances 0.000 description 1
210000004369 blood Anatomy 0.000 description 1
230000036765 blood level Effects 0.000 description 1
238000009835 boiling Methods 0.000 description 1
229940124630 bronchodilator Drugs 0.000 description 1
239000004067 bulking agent Substances 0.000 description 1
239000000969 carrier Substances 0.000 description 1
230000008859 change Effects 0.000 description 1
LOUPRKONTZGTKE-UHFFFAOYSA-N cinchonine Natural products C1C(C(C2)C=C)CCN2C1C(O)C1=CC=NC2=CC=C(OC)C=C21 LOUPRKONTZGTKE-UHFFFAOYSA-N 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
239000000850 decongestant Substances 0.000 description 1
229940124581 decongestants Drugs 0.000 description 1
206010061428 decreased appetite Diseases 0.000 description 1
238000004090 dissolution Methods 0.000 description 1
239000002934 diuretic Substances 0.000 description 1
229940030606 diuretics Drugs 0.000 description 1
229960001484 edetic acid Drugs 0.000 description 1
230000002526 effect on cardiovascular system Effects 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
229960005309 estradiol Drugs 0.000 description 1
229930182833 estradiol Natural products 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
235000013305 food Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
-1 geriatrics Substances 0.000 description 1
239000011521 glass Substances 0.000 description 1
238000010438 heat treatment Methods 0.000 description 1
229930195733 hydrocarbon Natural products 0.000 description 1
150000002430 hydrocarbons Chemical class 0.000 description 1
229910052500 inorganic mineral Inorganic materials 0.000 description 1
239000000252 konjac Substances 0.000 description 1
235000010485 konjac Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
239000011707 mineral Substances 0.000 description 1
235000010755 mineral Nutrition 0.000 description 1
238000002156 mixing Methods 0.000 description 1
239000007932 molded tablet Substances 0.000 description 1
229940035363 muscle relaxants Drugs 0.000 description 1
239000003158 myorelaxant agent Substances 0.000 description 1
229930014626 natural product Natural products 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
239000007764 o/w emulsion Substances 0.000 description 1
238000004806 packaging method and process Methods 0.000 description 1
229960005489 paracetamol Drugs 0.000 description 1
239000002245 particle Substances 0.000 description 1
230000002572 peristaltic effect Effects 0.000 description 1
239000000546 pharmaceutical excipient Substances 0.000 description 1
239000006187 pill Substances 0.000 description 1
230000036470 plasma concentration Effects 0.000 description 1
239000004584 polyacrylic acid Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
OIGNJSKKLXVSLS-VWUMJDOOSA-N prednisolone Chemical compound O=C1C=C[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 OIGNJSKKLXVSLS-VWUMJDOOSA-N 0.000 description 1
229960005205 prednisolone Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000000069 prophylactic effect Effects 0.000 description 1
210000001187 pylorus Anatomy 0.000 description 1
229960001404 quinidine Drugs 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000008107 starch Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
229920001059 synthetic polymer Polymers 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
239000002562 thickening agent Substances 0.000 description 1
239000003204 tranquilizing agent Substances 0.000 description 1
230000002936 tranquilizing effect Effects 0.000 description 1
235000015112 vegetable and seed oil Nutrition 0.000 description 1
239000008158 vegetable oil Substances 0.000 description 1
229940088594 vitamin Drugs 0.000 description 1
229930003231 vitamin Natural products 0.000 description 1
235000013343 vitamin Nutrition 0.000 description 1
239000011782 vitamin Substances 0.000 description 1
239000001993 wax Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0065—Forms with gastric retention, e.g. floating on gastric juice, adhering to gastric mucosa, expanding to prevent passage through the pylorus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Medicinal Preparation (AREA)

CA000505778A 1985-04-12 1986-04-03 Compositions therapeutiques flottantes a liberation lente Expired CA1269043A (fr)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
CA000505778A CA1269043A (fr)	1985-04-12	1986-04-03	Compositions therapeutiques flottantes a liberation lente

Applications Claiming Priority (5)

Application Number	Priority Date	Filing Date	Title
US72283285A	1985-04-12	1985-04-12
US722,832		1985-04-12
CA000505778A CA1269043A (fr)	1985-04-12	1986-04-03	Compositions therapeutiques flottantes a liberation lente
US026,640		1987-03-17
US07/026,640 US4814179A (en)	1985-04-12	1987-03-17	Floating sustained release therapeutic compositions

Publications (2)

Publication Number	Publication Date
CA1269043C CA1269043C (fr)	1990-05-15
CA1269043A true CA1269043A (fr)	1990-05-15

Family

ID=26701481

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CA000505778A Expired CA1269043A (fr)	1985-04-12	1986-04-03	Compositions therapeutiques flottantes a liberation lente

Country Status (1)

Country	Link
CA (1)	CA1269043A (fr)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102824326A (zh) *	2012-09-27	2012-12-19	中国药科大学	一种新型稳定的缓释软胶囊及其制备方法

1986
- 1986-04-03 CA CA000505778A patent/CA1269043A/fr not_active Expired

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN102824326A (zh) *	2012-09-27	2012-12-19	中国药科大学	一种新型稳定的缓释软胶囊及其制备方法

Also Published As

Publication number	Publication date
CA1269043C (fr)	1990-05-15

Legal Events

Date	Code	Title	Description
1992-11-17	MKLA	Lapsed
2023-05-26	MKLA	Lapsed	Effective date: 19921117

Publication	Publication Date	Title
US4814179A (en)	1989-03-21	Floating sustained release therapeutic compositions
US4167558A (en)	1979-09-11	Novel sustained release tablet formulations
US4140755A (en)	1979-02-20	Sustained release tablet formulations
EP0250038B1 (fr)	1991-08-21	Capsule à libération retardée
ES2301537T3 (es)	2008-07-01	Comprimidos y formulacion de guaifenesina de liberacion sostenida.
CA1073358A (fr)	1980-03-11	Formulations a liberation prolongee
KR880001090B1 (ko)	1988-06-23	디피리다몰의 경구용 제형의 제조방법
US5382601A (en)	1995-01-17	Memantine-containing solid pharmaceutical dosage forms having an extended two-stage release profile and production thereof
US6955821B2 (en)	2005-10-18	Sustained release formulations of guaifenesin and additional drug ingredients
FI113336B (fi)	2004-04-15	Menetelmä tramadolisuolaa sisältävän lääkeaineen valmistamiseksi, jolla on viivästynyt vaikuttavan aineen vapautuminen
JP2617109B2 (ja)	1997-06-04	経口投与用の持続的放出性薬剤の製剤
US4814178A (en)	1989-03-21	Floating sustained release therapeutic compositions
US20110177168A1 (en)	2011-07-21	Composition
EP0313328A1 (fr)	1989-04-26	Compositions à libération prolongée
KR100202154B1 (ko)	1999-06-15	파라세타몰 및 돔페리돈을 함유한 필름 피복 정제
JPS6322032A (ja)	1988-01-29	ゼラチン封入徐放性組成物及びその製造方法
JPH05271054A (ja)	1993-10-19	口腔内溶解型錠剤およびその製造法
AU2001255680A1 (en)	2002-01-31	Guaifenesin sustained release formulation and tablets
KR20100126266A (ko)	2010-12-01	약학 조성물
JPH0625064B2 (ja)	1994-04-06	制御放出塩化カリウム
US4155993A (en)	1979-05-22	Prolonged-release pharmaceutical compositions for oral administration, their methods of making and use
WO1992004013A1 (fr)	1992-03-19	Systeme de matrice a effet retard et particules multiples
EP0198769A2 (fr)	1986-10-22	Compositions thérapeutiques flottantes à libération prolongée
EP0425298B1 (fr)	1994-04-13	Préparation à libération retardée d'un chlorhydrate d'un médicament basique
US5633005A (en)	1997-05-27	Dimeticon pastilles

CA1269043A - Compositions therapeutiques flottantes a liberation lente - Google Patents

Info

Links

Classifications

Landscapes

Priority Applications (1)

Applications Claiming Priority (5)

Publications (2)

Family

ID=26701481

Family Applications (1)

Country Status (1)

Cited By (1)

Cited By (1)

Also Published As

Similar Documents

Legal Events